

Astellas Announces Changes in Personnel and Sales and Marketing Structure in Japan

Tokyo, August 20, 2015 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced the changes in personnel and Sales and Marketing structure in Japan as below.

1. Appointment of Corporate Executive effective on October 1, 2015

| Name | New Title | Current Title |
|----------------|--|--|
| Nobuaki Tanaka | Divisional Senior Vice President, Strategic Business Management, Japan Sales & Marketing | General Manager, Chiba Branch, Japan Sales & Marketing |

2. Personnel changes effective on October 1, 2015

| Name | New Title | Current Title |
|----------------|---|--|
| Masaaki Hirano | Vice President, Medicinal Chemistry Research Labs., Drug Discovery Research | Senior Director, Medicinal Chemistry Research Labs., Drug Discovery Research |
| Naohiro Yamada | General Manager, Tohoku Branch, Japan Sales & Marketing | General Manager, Shikoku Branch, Japan Sales & Marketing |
| Masahiro Fuji | General Manager, Chiba Branch, Japan Sales & Marketing | Executive Director, Tokyo Branch, Japan Sales & Marketing |
| Tadashi Hara | General Manager, Nagoya Branch, Japan Sales & Marketing | Divisional Senior Vice President, Strategic Business Management, Japan Sales & Marketing |
| Yoshiyuki Naoi | General Manager, Shikoku Branch, Japan Sales & Marketing | Executive Director, Sapporo Branch, Japan Sales & Marketing |

[Appointments of Staff Executive Director effective on October 1, 2015]

| Name | New Title | Current Title |
|------------------|---|---|
| Takashi Shimizu | Staff Executive Director, External Relations | Executive Director, External Relations |
| Hiroshi Takemoto | Staff Executive Director, External Relations | Executive Director, External Relations |
| Mika Haga | Staff Executive Director, Legal & Compliance | Senior Manager, Legal & Compliance |
| Yoriko Suzuki | Staff Executive Director, Intellectual Property | Director, Intellectual Property |
| Rika Abe | Staff Executive Director, Medical Science, Medical Affairs, Japan | Director, Medical Science, Medical Affairs, Japan |

[Personnel change of affiliate effective on October 1, 2015]

| Name | New Title | Current Title |
|------------|--|--------------------------------|
| Koji Nagao | President, Astellas US Technologies, Inc. | Astellas US Technologies, Inc. |

3. Changes in Sales and Marketing Structure in Japan

With accelerating changes in the healthcare environment, Astellas will change to a new Sales (Medical Representative (MR)) structure that allows MR to provide further accurate medical information based on the flow of patient treatment by each region and by each individual medical institution, as of October 1, as outlined below.

- In order to provide a more detailed level of information tailored to the treatment status of individual patients, based on the treatment policies of each healthcare professional, the previous product specific representative system categorized by therapeutic area will be changed to a system in which each MR will, in principle, provide information on all products of Astellas.
- Also, in order to further effectively deliver the value offered by Astellas' specialty products to medical professionals, based on in-depth knowledge of the products and relevant diseases, a therapeutic area specialist will be newly introduced in three therapeutic areas - oncology, immunology and transplantation.

Through the information provision under the new Sales structure, Astellas strives to certainly deliver the product value and turn innovative science into value for patients.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

###

| |
|--|
| Contacts for inquiries or additional information |
| Astellas Pharma Inc. Corporate Communications TEL: 03-3244-3201 FAX: 03-5201-7473 http://www.astellas.com/en |